Search Dental Tribune

Interview: “Bioactive endodontics is the future”

Dr. James Bahcall and colleagues are exploring the possibilities of cryotherapy in endodontic dentistry. (Photograph: Dr. James Bahcall)
Monique Mehler, Dental Tribune International

Monique Mehler, Dental Tribune International

Mon. 8. July 2019

save

In the medical field, cryotherapy is used in an effort to relieve pain and swelling after soft-tissue management or surgery. Currently, researchers in the U.S. are exploring the possibilities and limitations of vital pulp cryotherapy in clinical trials. Dr. James Bahcall, who plays an important role in these investigations, is a clinical professor at the University of Illinois at Chicago. He spoke to Dental Tribune International about the studies.

Dr. Bahcall, in collaboration with other researchers, you have published an article titled “Introduction to vital pulp cryotherapy” in which the use of cold therapy in endodontics is explored. What is the history behind the use of  cryotherapy in vital pulp therapy?
There has been a paradigm shift in vital pulp therapy over the last three to five years. We have gained a better understanding of pulp biology from caries involvement, and there have been new developments in bioceramic materials. We have also come to view vital pulp therapy as a permanent rather than temporary dental treatment. All of this allowed us to develop vital pulp cryotherapy. Although we did not invent cryotherapy, we were the first to bring it into endodontics for vital pulp treatment. Medicine has demonstrated since the early 1960s that cryotherapy can reduce nerve pain response, inflammation and hemorrhaging, and can help reduce a patient’s need for postoperative pain medications.

Vital pulp cryotherapy is performed when a carious lesion is removed from a tooth and there is direct or indirect exposure of the dental pulp. The cryotherapy portion of treatment involves placing sterile ice on the exposed pulp. The application of ice lowers the temperature of the tooth’s blood and nerve supply, and this has been shown clinically to reduce inflammation and post-treatment tooth pain. It is important to note that, after performing the cryotherapy procedure, 17% EDTA irrigation is applied, a bioceramic material is then placed over the directly or indirectly exposed pulp, and the tooth is restored with a permanent restorative material, such as composite or amalgam.

How is this different from classic root canal therapy?
Vital pulp cryotherapy involves treating a carious tooth while maintaining the tooth’s pulpal tissue as opposed to root canal therapy that involves removal of the entire dental pulp and replacing it with gutta-percha and sealer.

What are the benefits of vital pulp cryotherapy, and what are its limitations?
The benefits of vital pulp cryotherapy are its ability to eliminate pulpal inflammation and a patient’s tooth pain without the complete removal of the dental pulp. By maintaining the dental pulp, we are able to maintain the tooth’s strength by not having to remove root dentin, the pulp–dentin complex and the pulp’s immune defense mechanisms. Another benefit of vital pulp cryotherapy is the treatment time for the patient. Once the patient is properly anesthetized and the caries is removed, the actual time to complete the vital pulp cryotherapy portion is 10–15 minutes. In comparison, root canal therapy can take 1–2 hours. Vital pulp therapy procedures are completed in one patient treatment visit.

The limitation of vital pulp cryotherapy is that this procedure can only be performed on vital teeth that can be permanently restored with composite or amalgam immediately after the procedure. It cannot be performed with necrotic or partially necrotic pulps. A clinician cannot prepare a vital pulp cryotherapy treated tooth for a crown. The reason for this is that, once the vital pulp cryotherapy is completed, you do not want to do any further dental treatment to this tooth because you risk the possibility of restimulating the pulpal inflammation.

In your article, you conclude that further clinical studies are needed in order to establish the long-term prognosis of a pulp after vital pulp cryotherapy. What are your expectations?
As with any new dental procedure, clinical cases and studies need to be published in peer-reviewed dental literature. Vital pulp cryotherapy is no different. We have published case reports and have been conducting clinical research on vital pulp cryotherapy. Our study has found that patients have less postoperative pain immediately after treatment and maintain normal pulp vitality at six months and at one year after treatment. This is as far as our clinical study has patient recalls at this point. Our expectations are, firstly, to demonstrate that this is a valid procedure for vital pulp treatment beyond one year. Secondly, we hope to encourage our dental colleagues to publish vital pulp cryotherapy case reports and clinical research in the dental literature.

How do you think vital pulp cryotherapy will advance endodontics?
We feel that vital pulp cryotherapy will help to broaden the type of pulpal treatment that we can provide to our patients. It also will be an important treatment component in bioactive endodontic therapy. Bioactive endodontics is the future. By definition, “bioactive” means having a biological effect. Bioactive endodontics in conventional endodontic treatment includes vital pulp cryotherapy and regenerative endodontics. It involves the use of bioactive materials and the patient’s own blood to help heal, as in the case of vital pulp cryotherapy, and to replace the gutta-percha and sealer in classic root canal therapy.

Tags:
To post a reply please login or register

Dental professionals gather in Kazakhstan for MegaGen’s Eurasia Scientific Meeting

Held in Astana in Kazakhstan, the 2026 Eurasia Scientific Meeting aimed to foster new connections between dental professionals in Central Asia. (All images: MegaGen)
Dental Tribune International

Dental Tribune International

Wed. 21. October 2026

save

ASTANA, Kazakhstan: In September, MegaGen hosted the 2026 Eurasia Scientific Meeting in Astana, convening around 230 dental professionals from Kazakhstan and neighbouring countries. The event provided a regional platform for clinical knowledge exchange and marked a further step in MegaGen’s efforts to expand academic networks and engagement in the region.

Held under the theme “Revolutionary advances on full mouth restorations with immediate implants”, the meeting combined presentations by international and local clinicians with the introduction of MegaGen products to the local market. Among the speakers was Dr Marcus Engelschalk, an oral surgeon from Germany, who discussed immediate implant placement at molar sites, focusing on treatment planning based on extraction socket conditions and strategies for achieving primary stability. Dr Engelschalk also discussed MegaGen’s IW Classification, a framework for assessing molar extraction sites before immediate implant placement.

Prof. Vygandas Rutkūnas, a prosthodontist at Vilnius University in Lithuania, presented digital full-mouth treatment protocols incorporating the BLUEDIAMOND IMPLANT and the AXA abutment. His presentation covered immediate implant placement and early loading.

Among the speakers from Kazakhstan, implantologist Dr Bekzhan Omeshbayev presented a fully digital protocol for rehabilitating partially and completely edentulous patients. Oral and maxillofacial surgeon Dr Temirlan Berkaliev discussed implant placement and soft-tissue grafting in the aesthetic zone. The local presentations also included clinical cases involving the AnyOne and AnyRidge implant systems.

Four products introduced to the Kazakhstan market

The meeting marked the Kazakhstan launch of MegaGen’s BLUEDIAMOND, BD Cuff and ARi implant systems, as well as the AXA abutment. The company also presented clinical solutions combining its implant systems and digital technologies to address a range of treatment challenges:

  • accelerated loading approaches across different bone densities;
  • implant treatment in cases involving insufficient bone volume or challenging ridge conditions; and
  • digital workflows extending from diagnosis and treatment planning to provisional restoration in full-mouth rehabilitation.

The 2026 Eurasia Scientific Meeting marked the Kazakhstan launch of MegaGen’s BlueDiamond, BD Cuff and ARi dental implant systems, as well as the AXA abutment.

The meeting also featured the New Toronto Declaration, first presented at the 19th MegaGen International Symposium in Toronto in Canada in June. The declaration outlines clinical principles emphasising anchorage in stable basal bone, the achievement of primary stability through implant design and appropriate surgical protocols, and patient-centred, minimally invasive treatment approaches.

Networking activities alongside the scientific programme provided opportunities for participants to exchange experiences with international speakers and colleagues from across the region. According to MegaGen, the 2026 Eurasia Scientific Meeting aimed to strengthen academic relationships and build closer connections with dental professionals throughout Central Asia.

The 20th MegaGen International Symposium will take place on 16 and 17 April 2027 in Shanghai in China. It will address immediate implant treatment protocols and management of peri-implantitis.

Tags:
To post a reply please login or register
advertisement
advertisement